Impact on Quality of Life by Moxibustion in Chemotherapy for Cancer

The Comprehensive and Integrative Medicine Institute of South Korea20 enrolled

Overview

Most cancer patients experience multiple symptoms related to chemotherapy and use CAM (complementary and alternative medicine) as an adjunct to conventional treatment. Moxibustion is traditional Korean medical therapeutic method and uses the heat generated by burning herbal preparations containing Artemisia vulgaris to stimulated acupoint. Herein, the investigators propose an open-label pilot study investigating the effectiveness of moxibustion stimulation at abdominal acupoint on quality of life in cancer patients under chemotherapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

SINGLE

Enrollment

Conditions

Cancer

Interventions

MoxibustionOTHER

In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion. The moxibustion will be removed when the patient feel hotness and require remove them

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnostic histopathology of cancer * Performance status of 0-2 on the European Cooperative Oncology Group (ECOG) performance scale. * Patients on chemotherapy currently have plan to receive chemotherapy for more than 6 weeks. * Follow-up possible during the clinical trial * Informed signed consent Exclusion Criteria: * Patients with Severe Heart disease and hypertension that is not controlled (systolic blood pressure \>160 or Diastolic blood pressure \>100) * Patients with diabetes that is not controlled (FBST \>180 or BST\>250) * Patients with abdominal injury or severe ascites can't be received moxibustion therapy on abdomen. * Hypersensitive section to moxibustion treatment * Inability to comprehend or express oneself in the Korean language * An Individual deemed to be ineligible by a physician * Refusal to participate in this trial or to provide informed consent.

Locations (1)

Deagu Hanny University Medical center

Deagu, South Korea

Outcomes

Primary Outcomes

functional Assessment of Cancer Therapy: General (FACT-G)

Time frame: change from baseline to 6 weeks

Secondary Outcomes

Body mass index

Time frame: change from baseline to 6 weeks

immune function

lymphocyte panel(CD3,4,8,19,26), WBC, Differential count

Time frame: change from baseline to 6 weeks

M.D, Anderson symptom Inventory (MDASI)

Time frame: change from baseline to 6 weeks

Central Contacts

Hyun Jung Jung, KMD, Ph. D

CONTACT

+82537702082 koreancarmen@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.